{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"59.9","upperLimit":"87.7","value":"77.1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"46"}],"units":"Participants"}],"description":"The progression free survival is the percentage of the patients without disease progression","dispersionType":"95% Confidence Interval","groups":[{"description":"Nivolumab 360 mg IV Q3W + Paclitaxel 200mg/m2 + Carboplatin AUC 6 IV Q3W in resectable stage IIIA N2-NSCLC adult patients followed by adjuvant treatment for 1 year with Nivolumab 240 mg IV Q2W for 4 months and Nivolumab 480mg Q4W for 8 months\n\nNivolumab 360 mg: Nivolumab 360 mg IV Q3W + Followed by adjuvant treatment for 1 year with Nivolumab 240 mg IV Q2W for 4 months and Nivolumab 480mg Q4W for 8 months\n\nPaclitaxel 200mg/m2: Paclitaxel 200mg/m2 IV Q3W\n\nCarboplatin AUC 6: Carboplatin AUC 6 IV Q3W","id":"OG000","title":"Arm 1"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"at 24 months from the first dose of neoadjuvant treatment","title":"Progression Free Survival","type":"PRIMARY","unitOfMeasure":"percentage of participants"}